



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Miri Seiberg et al.

Serial No. : 10/689,149

Art Unit:

Filed

: October 20, 2003

Examiner:

For

: TOPICAL ANTI-CANCER COMPOSITIONS AND METHODS OF

USE THEREOF

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

March 15, 2004

Andrea L. Colby
(Name of applicant, assignee, or Registered Representative)

(Signature)

march (5 7094

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with [] the
first or _second After Final Submission, therefore:
<pre>Statement in Accordance with §1.97(e) '</pre>
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

* ***	
•	
	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ / the fee of $$180.00$ as set forth
	in §1.17(p).
•	In accordance with §1.97(d), this Information
	Disclosure Statement is being filed after the mailing date of
	either a Final Action under §1.113 or a Notice of Allowance
	under §1.311 but before the payment of the Issue Fee.
	Applicant(s) hereby petition(s) for consideration of this
	Information Disclosure Statement. Included are: Statement in
•	Accordance with §1.97(e) as set forth below and the fee of
	\$180.00 as set forth in §1.17(p).
	○ Copies of each of the references listed on the
	attached Form PTO-1449 are enclosed herewith.
-	Copies of references listed on the attached Form PTO-
	1449 are enclosed herewith EXCEPT THAT:
-	
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.
•	
	Copies of only foreign patent documents and non-
	patent literature are enclosed in accordance with 37 CFR 1.98
	(a)(2). (The U.S. patents and each U.S. patent application
	publication listed on the attached Form PTO-1449 are not
	- 3 -
•	

losed because this U.S. patent application was filed after Yune 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i). \boxtimes There are no listed references which are not in the English language. The relevance of those listed references which are not in the English language is as follows: Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/J&J1886CIP1/ALC. This form is submitted in triplicate. Respectfully submitted, Reg. No. 30,194 Attorney for Applicants Johnson & Johnson One Johnson & Johnson Plaza

MAR 1 7 2004 W

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

a conconori or into interior arricos il displays a vana o in 2 de interioriament.			
Application Number	10/689,149		
Filing Date	October 20, 2003		
First Named Inventor	Miri Seiberg		
Group Art Unit			
Examiner Name			
Attorney Docket Number	J&J1886CIP1		

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Kind Code² Examiner Cite of Cited Document where relevant passages of Cited Document Initials or relevant figures appear Number (if known) No.1 mm-dd-yyyy

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or passages or relevant Cite Examiner mm-dd-yyyy Applicant of Cited Document figures appear Initials Office³ Number4 KindCode⁵ No.1 wo 99/04752 02-04-1999 A2 Johnson & Johnson

Examiner	Date	
Signature	Considered	

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.